A Phase 2 Study of Ruxolitinib in People With T-Cell Large Granular Lymphocytic Leukemia

Full Title

A Phase II Study Evaluating the Efficacy of Ruxolitinib in Patients with T-Cell Large Granular Lymphocytic Leukemia (T-LGLL)

Purpose

Researchers want to see if ruxolitinib works well as a treatment for T-cell large granular lymphocytic leukemia (T-LGLL). T-LGLL is a rare cancer of white blood cells called lymphocytes. The people in this study have T-LGLL that keeps growing even with treatment.

Ruxolitinib blocks certain proteins (namely, JAK proteins and STAT3) that play a role in cancer growth. It is taken orally (by mouth).

Contact

For more information and to see if you can join this study, please call Dr. Alison Moskowitz’s office at 646-608-3726.